Ketamine for Treatment Resistant Depression

This book brings together an international group of clinicians and researchers from a broad swath of inter-related disciplines to offer the most up-to-date information about clinical and preclinical research into ketamine and second-generation “ketamine-like” fast-acting antidepressants. Currently available antidepressant medications act through monoaminergic systems, are ineffective for many individuals suffering from depression, and are associated with a delayed onset of peak efficacy of several months. The unexpected emergence of ketamine, an anesthetic N-methyl-D-aspartate (NMDA) receptor antagonist, as a rapid-acting antidepressant has reinvigorated CNS drug discovery research and catalyzed investigation in patient populations historically ignored in antidepressant drug development programs, particularly treatment-resistant patients and those with suicidality. Recent industry and academic research efforts have coalesced to explore NMDA receptor and glutamatergic molecular targets that lack ketamine’s psychotomimetic side effects and abuse liability but retain its rapid onset of efficacy. However, many fundamental questions remain regarding the neurobiological mechanisms underlying ketamine’s rapid antidepressant effects and the puzzling persistence of benefits observed in some patients following a single dose. This book examines how insights from these studies are forging new conceptual models of the neurobiology of stress-related affective, anxiety, and addictive disorders and the nature of treatment resistance. It also discusses how ketamine’s rapid antidepressant effects provide a scientific platform to facilitate innovation in clinical trial designs pertaining to patient selection, choice of control group, outcome measures, and dose-optimization. This book brings together data and insights from this rapidly expanding and extraordinarily promising field of study. Readers will be able to extract integrated themes and useful insights from the material contained in these diverse chapters and appreciate the paradigm-shifting contributions of ketamine to modern psychiatry and clinical neuroscience research.

Produk Detail:

  • Author : Sanjay J. Mathew
  • Publisher : Springer
  • Pages : 155 pages
  • ISBN : 3319429256
  • Rating : 4/5 from 21 reviews
CLICK HERE TO GET THIS BOOKKetamine for Treatment Resistant Depression

Ketamine for Treatment-Resistant Depression

Ketamine for Treatment-Resistant Depression
  • Author : Sanjay J. Mathew,Carlos A. Zarate, Jr.
  • Publisher : Springer
  • Release : 25 November 2016
GET THIS BOOKKetamine for Treatment-Resistant Depression

This book brings together an international group of clinicians and researchers from a broad swath of inter-related disciplines to offer the most up-to-date information about clinical and preclinical research into ketamine and second-generation “ketamine-like” fast-acting antidepressants. Currently available antidepressant medications act through monoaminergic systems, are ineffective for many individuals suffering from depression, and are associated with a delayed onset of peak efficacy of several months. The unexpected emergence of ketamine, an anesthetic N-methyl-D-aspartate (NMDA) receptor antagonist, as a rapid-acting antidepressant

Ketamine for Treatment-Resistant Depression

Ketamine for Treatment-Resistant Depression
  • Author : Gustavo H. Vazquez,Carlos A. Zarate,Elisa Brietzke
  • Publisher : Academic Press
  • Release : 16 September 2020
GET THIS BOOKKetamine for Treatment-Resistant Depression

Ketamine for Treatment-Resistant Depression: Neurobiology and Applications provides a simple, evidence-based overview for neuropsychiatrists and translational researchers on this medication, its mechanisms of actions, eligibility of patients for treatment, and the preparation and implementation of ketamine clinics. Provides efficacy research on ketamine as a treatment for depression Identifies best practices for clinical use, both long-term and acute Discusses the molecular mechanisms and neurobiology of action

Treatment-resistant Mood Disorders

Treatment-resistant Mood Disorders
  • Author : Andre Carvalho,Roger McIntyre
  • Publisher : Oxford University Press, USA
  • Release : 01 May 2014
GET THIS BOOKTreatment-resistant Mood Disorders

Treatment-resistant major depression and bipolar disorder are highly prevalent and disabling conditions associated with substantial morbidity and mortality. The assessment and management of refractory patients with mood disorders is a major clinical challenge for mental health providers. Part of the Oxford Psychiatry Library (OPL) series, this pocketbook provides a concise view of the current definitions, assessment and evidence-based management of treatment-resistant mood disorders and reviews novel therapeutic targets for mood disorders, which may enhance the therapeutic armamentarium of clinicians in

Ketamine for Depression

Ketamine for Depression
  • Author : Dr. Stephen J. Hyde
  • Publisher : Xlibris Corporation
  • Release : 04 September 2015
GET THIS BOOKKetamine for Depression

Given the unacceptably high rates of suffering, disability and premature death experienced by people with treatment-resistant depression and the surprisingly low rates of problems arising from the use of ketamine to treat the disorder, this is a therapy that all patients and their doctors should be discussing. This book summarises the research that has been carried out into ketamine for the treatment of depression over the past 15 years and, most importantly, describes different ways of using ketamine that are both

Rapid Acting Antidepressants

Rapid Acting Antidepressants
  • Author : Anonim
  • Publisher : Academic Press
  • Release : 29 June 2020
GET THIS BOOKRapid Acting Antidepressants

The Advances in Pharmacology series presents a variety of chapters from the best authors in the field. Includes the authority and expertise of leading contributors in pharmacology Presents the latest release in the Advances in Pharmacology series

Hello I Want to Die Please Fix Me

Hello I Want to Die Please Fix Me
  • Author : Anna Mehler Paperny
  • Publisher : Random House Canada
  • Release : 06 August 2019
GET THIS BOOKHello I Want to Die Please Fix Me

NATIONAL BESTSELLER SHORTLISTED FOR THE HILARY WESTON WRITERS' TRUST PRIZE FOR NONFICTION Award-winning journalist Anna Mehler Paperny's stunning memoir chronicles with courageous honesty and uncommon eloquence her experience of depression and her quest to explore what we know and don't know about this disease that afflicts almost a fifth of the population--providing an invaluable guide to a system struggling to find solutions. As fascinating as it is heartrending, as outrageously funny as it is serious, it is a must-read for

Managing Treatment-Resistant Depression

Managing Treatment-Resistant Depression
  • Author : Joao Luciano de Quevedo,Patricio Riva-Posse,William V. Bobo
  • Publisher : Elsevier
  • Release : 29 April 2022
GET THIS BOOKManaging Treatment-Resistant Depression

Managing Treatment-Resistant Depression: Road to Novel Therapeutics defines TRD for readers, discussing the clinical and epidemiological predictors, economic burden and neurobiological factors. In addition, staging methods for treatment resistance are fully covered in this book, including serotonin specific reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, other classes of antidepressants, including tricyclic antidepressants and monoamine oxidase inhibitors, augmentation strategies, and newer antidepressant treatments like ketamine and esketamine. In addition, evidence supporting the use of psychotherapies and neuromodulation strategies are also reviewed. Written

The Ketamine Papers

The Ketamine Papers
  • Author : Phil Wolfson,Glenn Hartelius
  • Publisher : Unknown Publisher
  • Release : 01 November 2016
GET THIS BOOKThe Ketamine Papers

The Ketamine Papers opens the door to a broad understanding of this medicine's growing use in psychiatry and its decades of history providing transformative personal experiences. Now gaining increasing recognition as a promising approach to the treatment of depression, posttraumatic stress disorder (PTSD), and other psychological conditions, ketamine therapies offer new hope for patients and clinicians alike. With multiple routes of administration and practices ranging from anesthesia to psychotherapy, ketamine medicine is a diverse and rapidly growing field. The Ketamine

Ketamine

Ketamine
  • Author : Kenji Hashimoto,Soichiro Ide,Kazutaka Ikeda
  • Publisher : Springer Nature
  • Release : 05 March 2020
GET THIS BOOKKetamine

This book presents the latest data from basic research and clinical trials supporting the effectiveness of ketamine as a treatment for depression, bipolar disorder, and suicidal behavior, setting these positive findings within the context of the serious problem of ketamine abuse. The first part of the book focuses on the evidence regarding ketamine abuse, with specific reference to Asian countries, and discusses countermeasures and complication management. It then addresses the mechanisms underlying the antidepressant and side effects of ketamine, which

The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder

The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder
  • Author : American Psychiatric Association
  • Publisher : American Psychiatric Pub
  • Release : 11 January 2018
GET THIS BOOKThe American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder

Alcohol use disorder (AUD) is a major public health problem in the United States. The estimated 12-month and lifetime prevalence values for AUD are 13.9% and 29.1%, respectively, with approximately half of individuals with lifetime AUD having a severe disorder. AUD and its sequelae also account for significant excess mortality and cost the United States more than $200 billion annually. Despite its high prevalence and numerous negative consequences, AUD remains undertreated. In fact, fewer than 1 in 10 individuals in the United States with a 12

Treatment-resistant Depression Trd

Treatment-resistant Depression Trd
  • Author : Deborah Diaz
  • Publisher : Unknown Publisher
  • Release : 01 February 2017
GET THIS BOOKTreatment-resistant Depression Trd

Major Depressive Disorder (MDD) is a common and debilitating neuropsychiatric disorder with high economic and societal impact. Approximately 30% of subjects with MDD achieve full remission after treatment with conventional antidepressants resulting in a relevant percentage of patients suffering from treatment resistant depression (TRD). Treating TRD is a difficult challenge for psychiatrists due to the complexity of this disabling condition. In fact, TRD is generally associated with a poorer outcome, higher suicidal risk, more severe psychosocial impairment and physical disability when

Bayesian Approaches to Clinical Trials and Health-Care Evaluation

Bayesian Approaches to Clinical Trials and Health-Care Evaluation
  • Author : David J. Spiegelhalter,Keith R. Abrams,Jonathan P. Myles
  • Publisher : John Wiley & Sons
  • Release : 16 January 2004
GET THIS BOOKBayesian Approaches to Clinical Trials and Health-Care Evaluation

READ ALL ABOUT IT! David Spiegelhalter has recently joined the ranks of Isaac Newton, Charles Darwin and Stephen Hawking by becoming a fellow of the Royal Society. Originating from the Medical Research Council’s biostatistics unit, David has played a leading role in the Bristol heart surgery and Harold Shipman inquiries. Order a copy of this author’s comprehensive text TODAY! The Bayesian approach involves synthesising data and judgement in order to reach conclusions about unknown quantities and make predictions.